SGS completes new life science services lab in California
Further investment in labs is also planned in France
Pharmaceutical analytical and bioanalytical contract solutions provider SGS Life Science Services has completed the build of its Life Science Services laboratory in Carson, California – its fifth in North America.
The 8,000 ft2 GMP/GLP facility houses 6,000 ft2 of dedicated laboratory space and 2,000 ft2 of offices, conference rooms and client records. The laboratory will provide microbiological testing and bioanalytical services and will initially employ seven scientific staff, with room for expansion in relation to customer demand. It will be officially opened on 23 October.
'This strategic expansion to the West Coast will provide local support to the well-established Californian pharmaceutical and biotechnological community,' said Jeff McDonald, COO, SGS North America. 'The laboratory complements our existing bioanalytical offer and we look forward to welcoming existing and new clients to visit this state-of-the-art facility in October.'
The company plans a further investment in the French market, with a new facility in Villeneuve la Garenne. The new location, which will replace an existing laboratory in Clichy, is approximately 5km away. The new laboratory will be completed in Q2 of 2015.
With 21 laboratories offering contract analytical and bioanalytical services, SGS delivers harmonised solutions to large pharmaceutical and biotechnology firms via its wholly-owned global network present in North America, Europe and Asia.
In addition to testing services for the bio/pharmaceutical market, SGS also provides clinical trial management (Phase I to IV) and services encompassing data management and statistics, PK/PD modeling and simulation, pharmacovigilance and regulatory consultancy.
The inspection, verification, testing and certification company now has more than 80,000 employees and operates a network of over 1,650 offices and laboratories around the world. It has seen significant evolution over the past five years with biological testing now accounting for 35% of revenues.
The company has also just launched a searchable web-based database of analytical methods available in its GMP/GLP/GCP compliant laboratories. This new tool contains biopharmaceutical, biosafety, and bioanalysis methods, enabling companies to quickly and easily identify suitable methods to optimise R&D and manufacturing processes.